IP Library › Granted Patent US 12,240,797
Granted Patent B2
US 12,240,797 · App. 17/430,286 · Granted Mar 4, 2025

Method of preparing a DON prodrug from L-glutamic acid

Inventors: Jon Philip Lawson (Wildwood, MO); Robert Christian Wild (Murrieta, CA); Yiyang Shao (Beijing, CN); Jinchao Weng (Beijing, CN); Pavel Majer (Sykesville, MD); Ivan Šnajdr (Prague, CZ); Martin Hadzima (Kosice, SK); Lukáš Tenora (Kretín, CZ); Jinxiao Chu (Beijing, CN)
Assignee: DRACEN PHARMACEUTICALS, INC.
C07C249/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,240,797
App. No.
17/430,286
Granted
Mar 4, 2025
Kind
B2
Abstract

The present disclosure provides methods of preparing a compound of Formula (I): wherein R 1 , R 2 , and R 3 are as defined as set forth in the application. In one embodiment, a compound of Formula (I) is prepared in >95% chemical purity and >95% enantiomeric excess.

Claims (71)

1. A method of preparing a compound of Formula I:

the method comprising:

(a) reacting a compound of Formula II:

with diazomethane in a solvent at a temperature of about −78° C. to about 0° C., wherein:

X 1 is selected from the group consisting of halogen, benzotriazole,

R 1 is C 1 -C 4 alkyl;

R 2 is C 1 -C 4 alkyl;

R 3 is selected from the group consisting of C 1 -C 6 alkyl, (aryl)alkyl, and (heteroaryl)alkyl;

R 4a is selected from the group consisting of C 1 -C 8 alkyl and C 3 -C 8 cycloalkyl; and

R 4b is selected from the group consisting of C 1 -C 8 alkyl and —CF 3 .

2. The method of claim 1 , wherein:

X 1 is:

3. The method of claim 2 , wherein R 4a is ethyl.

4. The method of claim 1 , wherein the compound of Formula II is prepared in situ and reacted with diazomethane without isolation or purification.

5. The method of claim 1 , wherein the compound of Formula II:

wherein:

X 1 is:

and

R 4a is selected from the group consisting of C 1 -C 8 alkyl and C 3 -C 8 cycloalkyl;

is obtained by reacting a compound of Formula III:

wherein:

R 1 is C 1 -C 4 alkyl;

R 2 is C 1 -C 4 alkyl; and

R 3 is selected from the group consisting of C 1 -C 6 alkyl, (aryl)alkyl, and

(heteroaryl)alkyl;

with a compound having Formula IV:

wherein:

R 4a is selected from the group consisting of C 1 -C 8 alkyl and C 3 -C 8 cycloalkyl,

in a solvent in the presence of a base at a temperature of about −45° C. to about 20° C.

6. The method of claim 5 , wherein the compound of Formula III is obtained by reacting a compound of Formula V:

wherein:

R 1 is C 1 -C 4 alkyl;

R 2 is C 1 -C 4 alkyl;

R 3 is selected from the group consisting of C 1 -C 6 alkyl, (aryl)alkyl, and

(heteroaryl)alkyl; and

PG 1 is a protecting group,

with a deprotecting agent in a solvent at a temperature of about 0° C. to about 60° C.

7. The method of claim 6 , wherein PG 1 is aralkyl, and the deprotecting agent is hydrogen in the presence of a catalyst.

8. The method of claim 6 , wherein the compound of Formula V is obtained by reacting a compound of Formula VI:

wherein:

R 1 is C 1 -C 4 alkyl; and

PG 1 is a protecting group,

with a compound of Formula VII:

wherein:

R 2 is C 1 -C 4 alkyl; and

R 3 is selected from the group consisting of C 1 -C 6 alkyl, (aryl)alkyl, and

(heteroaryl)alkyl;

in a solvent in the presence of a coupling agent at a temperature of about 0° C. to about 60° C.

9. The method of claim 8 , wherein the coupling agent comprises dicyclohexylcarbodiimide, diisopropylcarbodiimide, and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide-HCl.

10. The method of claim 9 , wherein the coupling agent further comprises ethyl cyano(hydroximino)acetate.

11. The method of claim 8 , wherein the compound of Formula VI is obtained by reacting a compound of Formula VIII:

wherein:

R 1 is C 1 -C 4 alkyl;

PG 1 is a protecting group; and

PG is a protecting group,

with an amine deprotecting agent in a solvent at a temperature of about 0° C. to about 60° C.,

wherein the amine deprotecting agent selectively removes PG in the presence of PG 1 .

12. The method of claim 11 , wherein PG is selected from the group consisting of fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, and carboxybenzyl.

13. The method of claim 11 further comprising reacting the

with an acid in a solvent to form a salt that precipitates from solution.

14. The method of claim 11 wherein the compound of Formula VIII is obtained by reacting a compound of Formula IX:

with R 1 —X 2 , wherein:

R 1 is C 1 -C 4 alkyl; and

X 2 is selected from the group consisting of —OH and —Br,

in solvent.

15. The method of claim 1 , wherein R 1 is isopropyl.

16. The method of claim 1 , wherein R 2 is methyl.

17. The method of claim 1 , wherein R 3 is:

18. The method of claim 1 , wherein isopropyl (S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate is obtained in about 10-90% yield starting from a compound of Formula IX.

19. The method of claim 1 , wherein isopropyl (S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate is obtained in about 98% chemical purity or more starting from a compound of Formula IX.

20. The method of claim 1 , wherein isopropyl (S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate is obtained in about 98% ee or more starting from a compound of Formula IX.

Assignments (5)
SECURITY INTEREST Recorded Jul 12, 2023
From: DRACEN PHARMACEUTICALS, INC.
To: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT
Reel/Frame 064232/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AV CR, V.V.I.
To: DRACEN PHARMACEUTICALS, INC.
Reel/Frame 063913/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: MAJER, PAVEL; SNAJDR, IVAN; HADZIMA, MARTIN; TENORA, LUKÁS
To: ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AV CR, V.V.I.
Reel/Frame 063913/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: SHAO, YIYANG; CHU, JINXIAO; WENG, JINCHAO
To: DRACEN PHARMACEUTICALS, INC.
Reel/Frame 063913/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: LAWSON, JON PHILIP; WILD, ROBERT CHRISTIAN
To: DRACEN PHARMACEUTICALS, INC.
Reel/Frame 063913/0383 →
Priority Claims (1)
WO PCT/CN2019/074802 · Feb 11, 2019 · international
Continuity (1)
Related Publication 20220089522A1 · Mar 24, 2022
References Cited (31)
US 10336778B2 · Slusher et al. · 2019 [cited by applicant]
US 10568868B2 · Slusher et al. · 2020 [cited by applicant]
US 10738066B2 · Slusher et al. · 2020 [cited by applicant]
US 10799605B2 · Osterkamp et al. · 2020 [cited by applicant]
US 10842763B2 · Slusher et al. · 2020 [cited by applicant]
US 10954257B2 · Slusher et al. · 2021 [cited by applicant]
US 20180221337A1 · Slusher et al. · 2018 [cited by applicant]
US 20180221395A1 · Slusher et al. · 2018 [cited by applicant]
US 20180222930A1 · Slusher et al. · 2018 [cited by applicant]
US 20190315783A1 · Slusher et al. · 2019 [cited by applicant]
US 20190315784A1 · Slusher et al. · 2019 [cited by applicant]
US 20220194898A1 · Lawson et al. · 2022 [cited by applicant]
JP 2005272404A · 2005 [cited by applicant]
JP 2017519001A · 2017 [cited by applicant]
WO WO2004113363A1 · 2004 [cited by applicant]
WO WO2017023774A1 · 2017 [cited by applicant]
WO WO2017023787A1 · 2017 [cited by applicant]
WO WO2017023791A1 · 2017 [cited by applicant]
WO WO2017023793A2 · 2017 [cited by applicant]
WO WO2019071110A1 · 2019 [cited by applicant]
WO WO2020167829A1 · 2020 [cited by applicant]
Abo-Ghalia, M., et al., “Synthesis of inhibitors of the meso-diaminopimelate—adding enzyme from [cited by applicant]
Pettit, G.R., et al., “Synthesis of azotomycin,” J. Org. Chem. 51(8):1282-1286, American Chemical Society, United States (Apr. 1986). [cited by applicant]
Montalbetti, C., et al., “Amine bond formation and peptide coupling,” Tetrahedron 61:10827-10852, Elsevier, Netherlands (Aug. 2005). [cited by applicant]
Ahluwalia, G.S., et al., “Metabolism and action of amino acid analog anti-cancer agents,” [cited by applicant]
Bitta, J., and Kubik, S., “Cyclic hexapeptides with free carboxylate groups as new receptors for monosaccharides,” [cited by applicant]
Hobbs, M.J., et al., “Elevation of Endogenous Nucleophiles in Rat Lung by Cysteine and Glutathione Esters [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/017750, Commissioner for Patents, United States, mailed on Apr. 29, 2020, 7 pages. [cited by applicant]
Lynch, G., et al., “Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma,” [cited by applicant]
Moss, G.P., “Basic Terminology of Stereochemistry,” [cited by applicant]
Rosenfeld, H., and Roberts, J., “Enhancement of Antitumor Activity of Glutamine Antagonists 6-Diazo-5-oxo-L-norleucine and Acivicin in Cell Culture by Glutaminase-Asparaginase,” [cited by applicant]